Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2010

01-08-2010 | Preclinical study

Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis

Authors: Sarah Khalid, David Hwang, Yael Babichev, Rani Kolli, Svetlana Altamentova, Shlomit Koren, Pamela J. Goodwin, Marguerite Ennis, Michael Pollak, Nahum Sonenberg, I. George Fantus

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

The mechanism of the association between breast cancer and obesity remains unknown. To investigate this mice over-expressing HER2/Neu in the mammary gland (MMTV-HER2/Neu) were fed either a high-fat diet (45% of calories) (HFD) or low-fat diet (10%) (LFD) from 4 weeks of age and followed for up to 1 year, or sacrificed when a mammary tumor reached 1.5 cm. There was a small but significant increase in body weight on HFD (P < 0.05) and the HFD mice displayed a greater fat mass determined by MRI (P < 0.01). Mild glucose intolerance was observed from 3 months of age on HFD, but insulin levels were not elevated. While the time of onset of a first tumor and tumor growth rates were not altered, mice on HFD had an earlier onset of a second tumor and a twofold greater incidence (LFD 25%, HFD 54%) and a greater absolute number of multiple tumors (tumors/mouse, LFD 1.5 ± 0.25 vs. HFD 2.7 ± 0.23, P < 0.01). Consistent with a lack of hyperinsulinemia, immunoblotting of skeletal muscle lysates from mice injected with insulin showed no insulin resistance determined by the phosphorylation of Akt/PKB. Similarly, there was no difference in basal or maximum insulin-stimulated phosphorylation of IRS-1/2, Akt/PKB, or p70 S6K in tumor cell lysates from HFD and LFD groups. Immunohistochemistry revealed no difference in tumor tissue staining for the proliferative marker, Ki67, between diets. These data indicate that HFD, in the absence of significant insulin resistance, mediates a tumor promoting, but not a tumor growth effect in this model of mammary carcinogenesis.
Literature
1.
2.
go back to reference Armstrong K, Eisen A, Weber B (2000) Assessing the risk of breast cancer. N Engl J Med 342:564–571CrossRefPubMed Armstrong K, Eisen A, Weber B (2000) Assessing the risk of breast cancer. N Engl J Med 342:564–571CrossRefPubMed
3.
go back to reference King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed
4.
5.
go back to reference Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRefPubMed Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRefPubMed
6.
go back to reference Cleary MP, Maihle NJ (1997) The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 216:28–43PubMed Cleary MP, Maihle NJ (1997) The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 216:28–43PubMed
7.
go back to reference Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151PubMedCrossRef
8.
go back to reference Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116:26–32PubMed Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW (1992) Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med 116:26–32PubMed
9.
go back to reference Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 10:33–42CrossRefPubMed Manjer J, Kaaks R, Riboli E, Berglund G (2001) Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev 10:33–42CrossRefPubMed
10.
go back to reference Expert Panel on Detection, evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
11.
go back to reference Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome. A new worldwide definition. Lancet 366:1059–1062CrossRefPubMed Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome. A new worldwide definition. Lancet 366:1059–1062CrossRefPubMed
12.
go back to reference Meigs JB (2003) Epidemiology of the insulin resistance syndrome. Curr Diabetes Rep 3:73–79CrossRef Meigs JB (2003) Epidemiology of the insulin resistance syndrome. Curr Diabetes Rep 3:73–79CrossRef
13.
go back to reference Sinagra D, Amato C, Scarpilta AM, Briganda M, Amato M, Saura G, Latteri MA, Caimi G (2002) Metabolic syndrome and breast cancer risk. Eur Rev Med Pharmacol Sci 6:55–59PubMed Sinagra D, Amato C, Scarpilta AM, Briganda M, Amato M, Saura G, Latteri MA, Caimi G (2002) Metabolic syndrome and breast cancer risk. Eur Rev Med Pharmacol Sci 6:55–59PubMed
14.
go back to reference Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:s823–s835PubMed Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86:s823–s835PubMed
15.
go back to reference Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE (2003) Type 2 Diabetes and subsequent incidence of breast cancer in the nurses’ health study. Diabetes Care 26:1752–1758CrossRefPubMed Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE (2003) Type 2 Diabetes and subsequent incidence of breast cancer in the nurses’ health study. Diabetes Care 26:1752–1758CrossRefPubMed
16.
go back to reference Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303–309CrossRefPubMed Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE (2006) Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303–309CrossRefPubMed
17.
go back to reference DelGiudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111–120CrossRef DelGiudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111–120CrossRef
18.
go back to reference Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51CrossRefPubMed Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51CrossRefPubMed
19.
go back to reference Borugian MJ, Sheps SB, Kim-Sing C, VanPatten C, Potter JD, Dunn B, Gallagher RP, Hislop TG (2004) Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 13:1163–1172PubMed Borugian MJ, Sheps SB, Kim-Sing C, VanPatten C, Potter JD, Dunn B, Gallagher RP, Hislop TG (2004) Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 13:1163–1172PubMed
20.
go back to reference Lawlor DA, Smith GD, Ebrahim S (2004) Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women’s Heart and Health Study. Cancer Causes Control 15:267–275CrossRefPubMed Lawlor DA, Smith GD, Ebrahim S (2004) Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women’s Heart and Health Study. Cancer Causes Control 15:267–275CrossRefPubMed
21.
go back to reference Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-1 receptor. Mol Carcinog 18:19–25CrossRefPubMed Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-1 receptor. Mol Carcinog 18:19–25CrossRefPubMed
22.
23.
go back to reference Braden LM, Carroll KK (1986) Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. Lipids 21:285–288CrossRefPubMed Braden LM, Carroll KK (1986) Dietary polyunsaturated fat in relation to mammary carcinogenesis in rats. Lipids 21:285–288CrossRefPubMed
24.
go back to reference Hakkak R, Holley AW, Macleod SL, Simpson PM, Fuchs GJ, Jo CH, Kieber-Emmons T, Korourian S (2005) Obesity promotes 7, 12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res 7:R627–R633CrossRefPubMed Hakkak R, Holley AW, Macleod SL, Simpson PM, Fuchs GJ, Jo CH, Kieber-Emmons T, Korourian S (2005) Obesity promotes 7, 12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res 7:R627–R633CrossRefPubMed
25.
go back to reference Rose DP, Hatala MA, Connolly JM, Rayburn J (1993) Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice. Cancer Res 53:4686–4690PubMed Rose DP, Hatala MA, Connolly JM, Rayburn J (1993) Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in nude mice. Cancer Res 53:4686–4690PubMed
26.
go back to reference Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD (2008) Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 60:534–541CrossRefPubMed Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD (2008) Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 60:534–541CrossRefPubMed
27.
go back to reference Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovski L, Hursting SD, Vinson C (2006) Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 66:5469–5476CrossRefPubMed Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovski L, Hursting SD, Vinson C (2006) Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 66:5469–5476CrossRefPubMed
28.
go back to reference Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P (1989) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:707–712CrossRef Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P (1989) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:707–712CrossRef
29.
go back to reference Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068–7077PubMed Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068–7077PubMed
30.
go back to reference Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582CrossRefPubMed Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582CrossRefPubMed
31.
go back to reference Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835–842PubMed Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835–842PubMed
32.
go back to reference Anai M, Funaki M, Ogihara T, Kanda A, Onishi Y, Sakoda H, Inukai K, Nawano M, Fukushima Y, Yazaki Y, Kikuchi M, Oka Y, Asano T (1999) Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 48:158–169CrossRefPubMed Anai M, Funaki M, Ogihara T, Kanda A, Onishi Y, Sakoda H, Inukai K, Nawano M, Fukushima Y, Yazaki Y, Kikuchi M, Oka Y, Asano T (1999) Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 48:158–169CrossRefPubMed
33.
go back to reference Wolf G, Trub T, Ottinger E, Groninga L, Lynch A, White MF, Miyazaki M, Lee J, Shoelson SE (1995) PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. J Biol Chem 270:27407–27410CrossRefPubMed Wolf G, Trub T, Ottinger E, Groninga L, Lynch A, White MF, Miyazaki M, Lee J, Shoelson SE (1995) PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. J Biol Chem 270:27407–27410CrossRefPubMed
34.
go back to reference Hu CC, Qing K, Chen Y (2004) Diet-induced changes in stearoyl-CoA desaturase 1 expression in obesity-prone and -resistant mice. Obes Res 12:1264–1270CrossRefPubMed Hu CC, Qing K, Chen Y (2004) Diet-induced changes in stearoyl-CoA desaturase 1 expression in obesity-prone and -resistant mice. Obes Res 12:1264–1270CrossRefPubMed
35.
go back to reference Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138–1143CrossRefPubMed Perreault M, Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7:1138–1143CrossRefPubMed
36.
go back to reference Stoll BA (1998) Western diet, early puberty, and breast cancer risk. Breast Cancer Res Treat 49:187–193CrossRefPubMed Stoll BA (1998) Western diet, early puberty, and breast cancer risk. Breast Cancer Res Treat 49:187–193CrossRefPubMed
37.
go back to reference MacMahon B, Trichopoulos D, Brown J, Andersen AP, Cole P, deWaard F, Kauraniemi T, Polychronopoulou A, Ravnihar B, Stormby N, Westlund K (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30:427–431CrossRefPubMed MacMahon B, Trichopoulos D, Brown J, Andersen AP, Cole P, deWaard F, Kauraniemi T, Polychronopoulou A, Ravnihar B, Stormby N, Westlund K (1982) Age at menarche, urine estrogens and breast cancer risk. Int J Cancer 30:427–431CrossRefPubMed
38.
go back to reference Stoll BA, Vatten LJ, Kvinnsland S (1994) Does early physical maturity influence breast cancer risk? Acta Oncol 33:171–176CrossRefPubMed Stoll BA, Vatten LJ, Kvinnsland S (1994) Does early physical maturity influence breast cancer risk? Acta Oncol 33:171–176CrossRefPubMed
39.
go back to reference Clavel-Chapelon F, Launoy G, Auquier A, Gairard B, Bremond A, Piana L, Lansac J, Renaud R (1995) Reproductive factors and breast cancer risk. Effect of age at diagnosis. Ann Epidemiol 5:315–320CrossRefPubMed Clavel-Chapelon F, Launoy G, Auquier A, Gairard B, Bremond A, Piana L, Lansac J, Renaud R (1995) Reproductive factors and breast cancer risk. Effect of age at diagnosis. Ann Epidemiol 5:315–320CrossRefPubMed
40.
go back to reference Stoll BA (1998) Teenage obesity in relation to breast cancer risk. Int J Obes Relat Metab Disord 22:1035–1040CrossRefPubMed Stoll BA (1998) Teenage obesity in relation to breast cancer risk. Int J Obes Relat Metab Disord 22:1035–1040CrossRefPubMed
41.
go back to reference Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12:S99–S111CrossRefPubMed Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12:S99–S111CrossRefPubMed
42.
go back to reference Stoll BA (1998) Essential fatty acids, insulin resistance, and breast cancer risk. Nutr Cancer 31:72–77CrossRefPubMed Stoll BA (1998) Essential fatty acids, insulin resistance, and breast cancer risk. Nutr Cancer 31:72–77CrossRefPubMed
43.
go back to reference Cleary MP, Grande JP, Maihle NJ (2004) Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice. Int J Obes Relat Metab Disord 28:956–962CrossRefPubMed Cleary MP, Grande JP, Maihle NJ (2004) Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice. Int J Obes Relat Metab Disord 28:956–962CrossRefPubMed
44.
go back to reference Cleary MP, Grande JP, Juneja SC, Maihle NJ (2004) Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 50:174–180CrossRefPubMed Cleary MP, Grande JP, Juneja SC, Maihle NJ (2004) Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 50:174–180CrossRefPubMed
45.
go back to reference Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13:292–379CrossRef Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13:292–379CrossRef
46.
go back to reference Papa V, Costantino A, Belfiore A (1997) Insulin receptor what role in breast cancer? Trends Endocrinol Metab 8:306–312CrossRefPubMed Papa V, Costantino A, Belfiore A (1997) Insulin receptor what role in breast cancer? Trends Endocrinol Metab 8:306–312CrossRefPubMed
47.
go back to reference Hardy S, Langelier Y, Prentki M (2000) Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res 60:6353–6358PubMed Hardy S, Langelier Y, Prentki M (2000) Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res 60:6353–6358PubMed
48.
go back to reference Saadatian-Elahi M, Norat T, Goudable J, Riboli E (2004) Biomarkers of dietary fatty acid intake and the risk of breast cancer: a meta-analysis. Int J Cancer 111:584–591CrossRefPubMed Saadatian-Elahi M, Norat T, Goudable J, Riboli E (2004) Biomarkers of dietary fatty acid intake and the risk of breast cancer: a meta-analysis. Int J Cancer 111:584–591CrossRefPubMed
50.
go back to reference Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22:625–638CrossRefPubMed Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22:625–638CrossRefPubMed
51.
go back to reference Somasundar P, Yu AK, Vona-Davis L, McFadden DW (2003) Differential effects of leptin on cancer in vitro. J Surg Res 113:50–55CrossRefPubMed Somasundar P, Yu AK, Vona-Davis L, McFadden DW (2003) Differential effects of leptin on cancer in vitro. J Surg Res 113:50–55CrossRefPubMed
52.
go back to reference Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N (2005) Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23:6037–6042CrossRefPubMed Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N (2005) Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 23:6037–6042CrossRefPubMed
53.
go back to reference Ukkola O, Santaniemi M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80:696–702CrossRefPubMed Ukkola O, Santaniemi M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80:696–702CrossRefPubMed
54.
go back to reference Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107CrossRefPubMed Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107CrossRefPubMed
55.
go back to reference Wang Y, Lam JB, Lam KSL, Liu J, Lam MC, Hoo RLC, Wu D, Cooper GJS, Xu A (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462–11470CrossRefPubMed Wang Y, Lam JB, Lam KSL, Liu J, Lam MC, Hoo RLC, Wu D, Cooper GJS, Xu A (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462–11470CrossRefPubMed
56.
go back to reference Wang Y, Lam JB, Xu A (2007) Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 17:280–282CrossRefPubMed Wang Y, Lam JB, Xu A (2007) Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 17:280–282CrossRefPubMed
58.
go back to reference Young CD, Anderson SM (2008) Sugar and fat—that’s where it’s at: metabolic changes in tumors. Breast Cancer Res 10:202CrossRefPubMed Young CD, Anderson SM (2008) Sugar and fat—that’s where it’s at: metabolic changes in tumors. Breast Cancer Res 10:202CrossRefPubMed
59.
go back to reference DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20CrossRefPubMed DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20CrossRefPubMed
60.
go back to reference Heiden MG, Cantley CC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef Heiden MG, Cantley CC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRef
61.
go back to reference DeSchrijver E, Brusselmansk K, Heyns W, Verhoeven G, Swinnen JV (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799–3804 DeSchrijver E, Brusselmansk K, Heyns W, Verhoeven G, Swinnen JV (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799–3804
62.
go back to reference Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res 66:5287–5294CrossRefPubMed Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V (2006) Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res 66:5287–5294CrossRefPubMed
Metadata
Title
Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis
Authors
Sarah Khalid
David Hwang
Yael Babichev
Rani Kolli
Svetlana Altamentova
Shlomit Koren
Pamela J. Goodwin
Marguerite Ennis
Michael Pollak
Nahum Sonenberg
I. George Fantus
Publication date
01-08-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0586-8

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine